Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Adenocarcinoma
/ diagnostic imaging
Adult
Aged
Amides
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Area Under Curve
Chemotherapy, Adjuvant
Female
Humans
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Neoadjuvant Therapy
Predictive Value of Tests
Protons
ROC Curve
Rectal Neoplasms
/ diagnostic imaging
CEST
amide proton transfer imaging
chemotherapy
diffusion-weighted imaging
rectal cancer
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
30
04
2018
revised:
28
05
2018
accepted:
02
06
2018
pubmed:
15
6
2018
medline:
6
5
2019
entrez:
15
6
2018
Statut:
ppublish
Résumé
The amount of proteins and peptides can be estimated with amide proton transfer (APT) imaging. Previous studies demonstrated the usefulness of APT imaging to predict tumor malignancy. We determined whether APT imaging can predict the tumor response to neoadjuvant chemotherapy (NAC) in patients with locally advanced rectal cancer (LARC). Seventeen patients with LARC who underwent a pretherapeutic magnetic resonance examination including APT imaging and NAC (at least two courses) were enrolled. The APT-weighted imaging (WI) signal intensity (SI) (%) was defined as magnetization transfer ratio asymmetry (MTR The mean APTWI SI of the low-response group (n = 12; 3.05 ± 1.61%) was significantly higher than that of the high-response group (n = 5; 1.14 ± 1.13%) (P = 0.029). The area under the curve for predicting the tumor response using the APTWI SI was 0.87. When ≥2.75% was used as an indicator of low-response status, 75% sensitivity and 100% specificity of the APTWI SI were obtained. Pretherapeutic APT imaging can predict the tumor response to NAC in patients with LARC.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The amount of proteins and peptides can be estimated with amide proton transfer (APT) imaging. Previous studies demonstrated the usefulness of APT imaging to predict tumor malignancy. We determined whether APT imaging can predict the tumor response to neoadjuvant chemotherapy (NAC) in patients with locally advanced rectal cancer (LARC).
METHODS
METHODS
Seventeen patients with LARC who underwent a pretherapeutic magnetic resonance examination including APT imaging and NAC (at least two courses) were enrolled. The APT-weighted imaging (WI) signal intensity (SI) (%) was defined as magnetization transfer ratio asymmetry (MTR
RESULTS
RESULTS
The mean APTWI SI of the low-response group (n = 12; 3.05 ± 1.61%) was significantly higher than that of the high-response group (n = 5; 1.14 ± 1.13%) (P = 0.029). The area under the curve for predicting the tumor response using the APTWI SI was 0.87. When ≥2.75% was used as an indicator of low-response status, 75% sensitivity and 100% specificity of the APTWI SI were obtained.
CONCLUSION
CONCLUSIONS
Pretherapeutic APT imaging can predict the tumor response to NAC in patients with LARC.
Substances chimiques
Amides
0
Protons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-146Subventions
Organisme : a Grant-in-Aid for Scientific Research (C), JSPS KAKENHI
ID : 25461833
Informations de copyright
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.